Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 144

1.

Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA.

Zaleski M, Kobilay M, Schroeder L, Debald M, Semaan A, Hettwer K, Uhlig S, Kuhn W, Hartmann G, Holdenrieder S.

Oncotarget. 2018 Apr 27;9(32):22523-22536. doi: 10.18632/oncotarget.25077. eCollection 2018 Apr 27.

2.

Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer.

Holdenrieder S, Molina R, Qiu L, Zhi X, Rutz S, Engel C, Kasper-Sauer P, Dayyani F, Korse CM.

Tumour Biol. 2018 Apr;40(4):1010428318772202. doi: 10.1177/1010428318772202.

PMID:
29701125
3.

Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation.

Rheude T, Pellegrini C, Schmid H, Trenkwalder T, Mayr NP, Joner M, Kasel AM, Holdenrieder S, Nunez J, Sanchis J, Bodi V, Schunkert H, Kastrati A, Hengstenberg C, Husser O.

Am J Cardiol. 2018 Feb 15;121(4):461-468. doi: 10.1016/j.amjcard.2017.11.020. Epub 2017 Nov 27.

PMID:
29306485
4.

Determinants of elevated carbohydrate antigen 125 in patients with severe symptomatic aortic valve stenosis referred for transcatheter aortic valve implantation.

Rheude T, Pellegrini C, Reinhard W, Trenkwalder T, Koenig W, Mayr NP, Joner M, Núñez J, Holdenrieder S, Schunkert H, Kastrati A, Hengstenberg C, Husser O.

Biomarkers. 2018 May;23(3):299-304. doi: 10.1080/1354750X.2018.1423706. Epub 2018 Jan 15.

PMID:
29297708
5.

Evaluation of cellulose pads as a method to detect cytomegalovirus DNA in neonatal urine.

Kipfmueller F, Jungbluth K, Eis-Hübinger AM, Reber U, Holdenrieder S, Gembruch U, Bartmann P, Mueller A.

Ann Clin Biochem. 2018 Jan 1:4563217750183. doi: 10.1177/0004563217750183. [Epub ahead of print]

PMID:
29216741
6.

A comparison of gamma-glutamyl transferase and alkaline phosphatase as prognostic markers in patients with coronary heart disease.

Ndrepepa G, Holdenrieder S, Cassese S, Fusaro M, Xhepa E, Laugwitz KL, Schunkert H, Kastrati A.

Nutr Metab Cardiovasc Dis. 2018 Jan;28(1):64-70. doi: 10.1016/j.numecd.2017.09.005. Epub 2017 Sep 23.

PMID:
29126670
7.

Circular RNA maps paving the road to biomarker development?

Görlach A, Holdenrieder S.

J Mol Med (Berl). 2017 Nov;95(11):1137-1141. doi: 10.1007/s00109-017-1603-8. No abstract available.

PMID:
29067477
8.

Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.

Dolscheid-Pommerich RC, Keyver-Paik M, Hecking T, Kuhn W, Hartmann G, Stoffel-Wagner B, Holdenrieder S.

Tumour Biol. 2017 Oct;39(10):1010428317730246. doi: 10.1177/1010428317730246.

PMID:
29034816
9.

[Multicenter Evaluation of A New Progastrin-releasing Peptide (ProGRP) Immunoassay across Europe and China].

Korse CM, Holdenrieder S, Zhi X, Zahng X, Qiu L, Geistanger A, Lisy MR, Wehnl B, Broek DVD, Escudero JM, Standop J, Hu M, Molina R.

Zhongguo Fei Ai Za Zhi. 2017 Aug 20;20(8):568-577. doi: 10.3779/j.issn.1009-3419.2017.08.12. Chinese.

10.

Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation.

Stundl A, Lünstedt NS, Courtz F, Freitag-Wolf S, Frey N, Holdenrieder S, Zur B, Grube E, Nickenig G, Werner N, Frank D, Sinning JM.

Am J Cardiol. 2017 Sep 15;120(6):986-993. doi: 10.1016/j.amjcard.2017.06.033. Epub 2017 Jun 29.

PMID:
28739033
11.

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.

Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S.

Oncoimmunology. 2017 Mar 31;6(5):e1310358. doi: 10.1080/2162402X.2017.1310358. eCollection 2017.

12.

Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.

Hermann N, Dressen K, Schroeder L, Debald M, Schildberg FA, Walgenbach-Bruenagel G, Hettwer K, Uhlig S, Kuhn W, Hartmann G, Holdenrieder S.

Tumour Biol. 2017 Jun;39(6):1010428317711381. doi: 10.1177/1010428317711381.

PMID:
28618926
13.

Prognostic value of alkaline phosphatase in patients with acute coronary syndromes.

Ndrepepa G, Holdenrieder S, Xhepa E, Cassese S, Fusaro M, Laugwitz KL, Schunkert H, Kastrati A.

Clin Biochem. 2017 Oct;50(15):828-834. doi: 10.1016/j.clinbiochem.2017.05.020. Epub 2017 Jun 1.

PMID:
28579339
14.

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.

Ormanns S, Haas M, Remold A, Kruger S, Holdenrieder S, Kirchner T, Heinemann V, Boeck S.

Int J Mol Sci. 2017 May 19;18(5). pii: E1094. doi: 10.3390/ijms18051094.

15.

Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.

Schröck A, Leisse A, de Vos L, Gevensleben H, Dröge F, Franzen A, Wachendörfer M, Schröck F, Ellinger J, Teschke M, Wilhelm-Buchstab T, Landsberg J, Holdenrieder S, Hartmann G, Field JK, Bootz F, Kristiansen G, Dietrich D.

Clin Chem. 2017 Jul;63(7):1288-1296. doi: 10.1373/clinchem.2016.270207. Epub 2017 May 17.

PMID:
28515105
16.

Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.

Dressen K, Hermann N, Manekeller S, Walgenbach-Bruenagel G, Schildberg FA, Hettwer K, Uhlig S, Kalff JC, Hartmann G, Holdenrieder S.

Anticancer Res. 2017 May;37(5):2477-2486.

PMID:
28476816
17.

Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.

Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F.

Br J Cancer. 2017 Apr 11;116(8):1037-1045. doi: 10.1038/bjc.2017.45. Epub 2017 Mar 9. Review.

18.

Clinically Meaningful Use of Blood Tumor Markers in Oncology.

Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F.

Biomed Res Int. 2016;2016:9795269. doi: 10.1155/2016/9795269. Epub 2016 Nov 30. Review.

19.

Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.

Dolscheid-Pommerich RC, Manekeller S, Walgenbach-Brünagel G, Kalff JC, Hartmann G, Wagner BS, Holdenrieder S.

Anticancer Res. 2017 Jan;37(1):353-359.

PMID:
28011514
20.

Immune checkpoint therapy for pancreatic cancer.

Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D.

World J Gastroenterol. 2016 Nov 21;22(43):9457-9476. Review.

Supplemental Content

Loading ...
Support Center